Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monotherapy with Ofatumumab for Relapsed/Refractory Splenic B-cell Marginal Zone Lymphoma (MORE)
2013-004916-23Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in splenic marginal zone lymphoma (SMZL), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Complete response rate. Started Feb 2014; status: completed.
02
Drugs
ofatumumab
03
Conditions
splenic marginal zone lymphoma (SMZL)
Beyond the preview
Go deeper on 2013-004916-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004916-23.